Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push
Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.
Zacks
More News
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.
Zacks
2 Microcaps With Gross Margin Catalysts
CSBR and CEPL have levers in place for Gross Margin improvement.
Zacks
Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation
Discover why Zacks rates Champions Oncology as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore CSBR's accelerating pharmacology services and expanding data initiatives amid execution risks and commercialization timing.
Zacks
Champions Oncology (NASDAQ:CSBR) Shares Cross Below 200-Day Moving Average - What's Next?
Champions Oncology (NASDAQ:CSBR) Stock Crosses Below Two Hundred Day Moving Average - Here's What Happened...
MarketBeat
Champions Oncology (NASDAQ:CSBR) Share Price Passes Below Two Hundred Day Moving Average - Time to Sell?
Champions Oncology (NASDAQ:CSBR) Stock Crosses Below Two Hundred Day Moving Average - Should You Sell...
MarketBeat
Champions Oncology (NASDAQ:CSBR) Stock Crosses Above Fifty Day Moving Average - Should You Sell?
Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Above Fifty Day Moving Average - Should You Sell...
MarketBeat
Champions Oncology (NASDAQ:CSBR) Stock Price Down 1.8% - Time to Sell?
Champions Oncology (NASDAQ:CSBR) Stock Price Down 1.8% - Time to Sell...
MarketBeat
Champions Oncology (CSBR) Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Insights Ahead: Champions Oncology's Quarterly Earnings
read more...
Benzinga

Advertisement|Remove ads.